Belmar Pharma Solutions

About

National compounding pharmacy organization operating six 503A patient-specific locations and two FDA-registered 503B outsourcing facilities (Belmar Select Outsourcing). Founded in 1985 with a primary focus on bioidentical hormone replacement therapy (BHRT). NABP-accredited across all locations — one of the few national compounding organizations to hold this across every site. LegitScript certified. Confirmed pharmacy partner for MEDVi and other GLP-1 telehealth platforms. Tirzepatide compounding no longer permitted following the end of the FDA shortage designation (March 2025). Semaglutide also removed from the shortage list (February 2025); patient-specific compounding continues but availability is evolving — verify directly. Note: Received an FDA Form 483 in 2015 (no formal warning letter issued); no current FDA enforcement actions on record.

Highlights

• NABP Accredited — all locations
• 503A + 503B licensed
• LegitScript certified
• Founded 1985
• Telehealth platform partner

Compliance & Accreditation

Peptides Available for Compounding

States Licensed